Bridge City Capital LLC Grows Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Bridge City Capital LLC lifted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 28.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 103,809 shares of the company's stock after acquiring an additional 22,773 shares during the quarter. Bridge City Capital LLC owned 0.18% of Harmony Biosciences worth $3,572,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares in the last quarter. Mendota Financial Group LLC raised its holdings in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after buying an additional 965 shares during the period. KBC Group NV lifted its stake in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares in the last quarter. Quantbot Technologies LP purchased a new position in Harmony Biosciences during the 3rd quarter valued at about $74,000. Finally, PNC Financial Services Group Inc. grew its position in Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after acquiring an additional 519 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Stock Up 0.4 %

Shares of HRMY traded up $0.14 during midday trading on Thursday, reaching $33.35. The stock had a trading volume of 308,911 shares, compared to its average volume of 530,202. The company has a market cap of $1.91 billion, a price-to-earnings ratio of 15.81, a PEG ratio of 0.47 and a beta of 0.82. The company's fifty day simple moving average is $36.13 and its two-hundred day simple moving average is $35.52. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Remove Ads

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. The company had revenue of $201.30 million for the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share. Equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Transactions at Harmony Biosciences

In other news, CFO Sandip Kapadia sold 1,775 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey Dierks sold 10,507 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,452 shares of company stock valued at $2,831,679. Corporate insiders own 30.80% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, February 25th. HC Wainwright decreased their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $53.33.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.